Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor

Contributed by: PR Newswire

Tags

ObliqueTherapeuticsAB

More Like This

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers

Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's Innovation and Entrepreneurship Prize

Renowned Pharma and Biotech Development Leader, Dr. Andreas Wallnöfer, is named to Optigo Biotherapeutics’ Board of Directors as the company advances to IND-enabling studies

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage

Hansa Biopharma announces key executive appointments to support continued growth

BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize